ceftaroline fosamil · Abbvie · NDA 200327
Teflaro
Earliest generic entry, as listed · earliest of 2 marketed strengths
10 Feb 2031
Blocked by patent: US 8247400.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8247400 | product, use U-282 | 10 Feb 2031 |
| US 9629861 | product | 21 Sep 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 200327 · 001 · RLD | powder, intravenous | 400MG/VIAL | 10 Feb 2031 |
| 200327 · 002 · RLD | powder, intravenous | 600MG/VIAL | 10 Feb 2031 |